Luca Gianni
Active 1982–2026
- 140
- Papers
- 55,269
- Citations
- 93
- h-index
- 138
- i10-index
Citations
Citation sources
Countries
Institutions
Fields
- Medicine58.7%
- Biochemistry, Genetics and Molecular Biology30.7%
- Immunology and Microbiology2.6%
- Materials Science2%
- Engineering1.9%
- Computer Science1%
- Other3.1%
Topics
- HER2/EGFR in Cancer Research8.5%
- Breast Cancer Treatment Studies7%
- Cancer Treatment and Pharmacology3.8%
- Cancer Immunotherapy and Biomarkers3.5%
- Monoclonal and Polyclonal Antibodies Research3.2%
- Advanced Breast Cancer Therapies3.2%
- Other70.8%
Coauthors
- Pinuccia Valagussa33
- Giampaolo Bianchini22
- José Baselga20
- Semiglazov Vf19
- Martine Piccart18
- Javier Cortés15
- Sibylle Loibl15
- Eva Ciruelos13
- Milvia Zambetti13
- Véronique Dièras13
- David Cameron12
- Giuseppe Viale12
- Mauro Mansutti12
- Gianni Bonadonna11
- Marco Colleoni11
- Michael Untch11
- Begoña Bermejo10
- Chiun‐Sheng Huang10
- Claudio Zamagni10
- Lucia Del Mastro10
- Marc Thill10
- Aňa Lluch9
- Christian Jackisch9
- Giulia Bianchi9
All papers
- Sacituzumab Govitecan in Metastatic Triple-Negative Breast Cancer
Authors: Aditya Bardia, Sara A. Hurvitz, Sara M. Tolaney, Delphine Loirat, Kevin Punie, Mafalda Oliveira, Adam Brufsky, Sagar Sardesai, Kevin Kalinsky, Amelia Zelnak, Robert Weaver, Tiffany A. Traina, Florence Dalenc, Philippe Aftimos, Filipa Lynce, Sami Diab, Javier Cortés, Joyce O’Shaughnessy, Véronique Dièras, Cristiano Ferrario, Peter Schmid, Lisa A. Carey, Luca Gianni, Martine Piccart, Sibylle Loibl, David M. Goldenberg, Quan Hong, Martin Olivo, Loretta M. Itri, Hope S. Rugo - New England Journal of Medicine 2021 cited by 1,543
- Pathological complete response and long-term clinical benefit in breast cancer: the CTNeoBC pooled analysis
Authors: Patricia Cortazar, Lijun Zhang, Michael Untch, Keyur Mehta, Joseph P. Costantino, Norman Wolmark, Hervé Bonnefoi, David Cameron, Luca Gianni, Pinuccia Valagussa, Sandra M. Swain, Tatiana M. Prowell, Sibylle Loibl, D. Lawrence Wickerham, Jan Bogaerts, José Baselga, Charles M. Perou, Gideon M. Blumenthal, Jens‐Uwe Blohmer, Eleftherios P. Mamounas, Jonas Bergh, Semiglazov Vf, Robert Justice, Holger Eidtmann, Soonmyung Paik, Martine Piccart, Rajeshwari Sridhara, Peter A. Fasching, Leen Slaets, Shenghui Tang, Bernd Gerber, Charles E. Geyer, Richard Pazdur, Nina Ditsch, Priya Rastogi, W. Eiermann, Gϋnter von Minckwitz - The Lancet 2014 cited by 4,710
- Treatment landscape of triple-negative breast cancer — expanded options, evolving needs
Authors: Giampaolo Bianchini, Carmine De Angelis, Luca Licata, Luca Gianni - Nature Reviews Clinical Oncology 2021 cited by 1,331
- Triple-negative breast cancer: challenges and opportunities of a heterogeneous disease
Authors: Giampaolo Bianchini, Justin M. Balko, Ingrid A. Mayer, Melinda E. Sanders, Luca Gianni - Nature Reviews Clinical Oncology 2016 cited by 3,072
- Trastuzumab Emtansine for HER2-Positive Advanced Breast Cancer
Authors: Sunil Verma, David Miles, Luca Gianni, Ian E. Krop, Manfred Welslau, José Baselga, Mark D. Pegram, Do‐Youn Oh, Véronique Dièras, Ellie Guardino, Fang Ting Liang, Michael W. Lu, Steven R. Olsen, Kim T. Blackwell - New England Journal of Medicine 2012 cited by 3,784
- HER2-positive breast cancer
Authors: Sibylle Loibl, Luca Gianni - The Lancet 2016 cited by 1,110
- Spatial predictors of immunotherapy response in triple-negative breast cancer
Authors: Xiao Qian Wang, Esther Danenberg, Chiun‐Sheng Huang, Daniel Egle, Maurizio Callari, Begoña Bermejo, Matteo Dugo, Claudio Zamagni, Marc Thill, Anton Anton, Stefania Zambelli, Stefania Russo, Eva Ciruelos, Richard Greil, Balázs Győrffy, Vladimir Semiglazov, Marco Colleoni, Catherine M. Kelly, Gabriella Mariani, Lucia Del Mastro, Olivia Biasi, Robert S. Seitz, Pinuccia Valagussa, Giuseppe Viale, Luca Gianni, Giampaolo Bianchini, H. Raza Ali - Nature 2023 cited by 325
- Efficacy and safety of neoadjuvant pertuzumab and trastuzumab in women with locally advanced, inflammatory, or early HER2-positive breast cancer (NeoSphere): a randomised multicentre, open-label, phase 2 trial
Authors: Luca Gianni, Tadeusz Pieńkowski, Young‐Hyuck Im, Laslo Roman, Ling‐Ming Tseng, Mei-Ching Liu, Aňa Lluch, Elżbieta Starosławska, Juan de la Haba-Rodríguez, Seock‐Ah Im, José Luiz Pedrini, Brigitte Poirier, Paolo Morandi, Semiglazov Vf, Vichien Srimuninnimit, Giulia Bianchi, Tania Szado, Jayantha Ratnayake, Graham Ross, Pinuccia Valagussa - The Lancet Oncology 2011 cited by 2,358
- Overall survival in the OlympiA phase III trial of adjuvant olaparib in patients with germline pathogenic variants in BRCA1/2 and high-risk, early breast cancer
Authors: Charles E. Geyer, Judy E. Garber, Richard D. Gelber, Greg Yothers, Manuel Taboada, L. Ross, Priya Rastogi, Karen Cui, Amal Arahmani, Gursel Aktan, Anne Armstrong, Mónica Arnedos, Judith Balmaña, Jonas Bergh, Judith M. Bliss, Suzette Delaloge, Susan M. Domchek, Andrea Eisen, F. Elsafy, L.E. Fein, Anitra Fielding, James M. Ford, Sue Friedman, Karen A. Gelmon, Luca Gianni, Michael Gnant, Simon J. Hollingsworth, Seock‐Ah Im, Agnes Jager, Oskar T. Johannsson, Sunil R. Lakhani, W Janni, Barbro Linderholm, T.-W. Liu, Niklas Loman, Larissa A. Korde, Sibylle Loibl, Peter C. Lucas, Frederik Marmé, E. Martinez de Dueñas, Robin McConnell, Kelly‐Anne Phillips, Martine Piccart, Giovanna Rossi, Rita K. Schmutzler, Elżbieta Senkus, Zhi-Ming Shao, Priyanka Sharma, Christian F. Singer, Tanja Španić, Elmar Stickeler, Masakazu Toi, Tiffany A. Traina, Giuseppe Viale, Gabriele Zoppoli, Y.H. Park, Rinat Yerushalmi, Huan Yang, D. Pang, Kyung Hae Jung, Audrey Mailliez, Zhaoqing Fan, Isabelle Tennevet, J. Zhang, T. Nagy, Gabe S. Sonke, Qiuhong Sun, Marina Parton, Marco Colleoni, Marcus Schmidt, Adam Brufsky, W. Razaq, Bella Kaufman, David Cameron, Christine Campbell, Andrew Tutt, P. Sevelda, Ferdinand Haslbauer, Monika Penzinger, Leopold Öhler, Christoph Tinchon, Richard Greil, Sonja Heibl, Rupert Bartsch, Viktor Wette, Christian F. Singer, Claudia Pasterk, Ruth Helfgott, Gunda Pristauz-Telsnigg, Herbert Stöger, A. Weltermann, Daniel Egle, I. Thiel, David Fuchs, Holger Rumpold, Kathrin Strasser‐Weippl, Beate Rautenberg, Volkmar Müller, Marcus Schmidt, Stefan Paepke and 509 more - Annals of Oncology 2022 cited by 447
- Long-term outcomes for neoadjuvant versus adjuvant chemotherapy in early breast cancer: meta-analysis of individual patient data from ten randomised trials
Authors: Bernard Asselain, William E. Barlow, John M.S. Bartlett, Jonas Bergh, Elizabeth Bergsten-Nordström, Judith M. Bliss, Francesco Boccardo, Clare Boddington, Jan Bogaerts, Gianni Bonadonna, Rosie Bradley, Étienne Brain, Jeremy Braybrooke, Philippe Broët, John Bryant, Julie Ann Burrett, David Cameron, Mike Clarke, Alan S. Coates, Robert L. Coleman, Raoul Charles Coombes, Candace R. Correa, Joe Costantino, Jack Cuzick, David N. Danforth, Nancy E. Davidson, Christina Davies, Lucy Davies, Angelo Di Leo, David Dodwell, Mitch Dowsett, Frances Duane, Vaughan Evans, Marianne Ewertz, Bernard Fisher, John Forbes, Leslie G. Ford, J.-C. Gazet, Richard D. Gelber, Lucy Gettins, Luca Gianni, Michael Gnant, Jon Godwin, Aron Goldhirsch, Pamela J. Goodwin, Richard Gray, Daniel F. Hayes, Catherine Hill, James N. Ingle, Reshma Jagsi, R. Jakesz, Sam James, Wolfgang Janni, Hui Liu, Zulian Liu, Caroline Lohrisch, Sibylle Loibl, Liz MacKinnon, Andreas Makris, Eleftherios P. Mamounas, Gurdeep Mannu, Miguel Martín, S. Mathoulin, L. Mauriac, Paul McGale, Theresa McHugh, Philip Morris, Hirofumi Mukai, Larry Norton, Yasuo Ohashi, Ivo A. Olivotto, Soon Young Paik, Hongchao Pan, Richárd Pető, Martine Piccart, Lori J. Pierce, Philip Poortmans, Trevor J. Powles, K.I. Pritchard, Joseph Ragaz, Vinod Raina, Peter M. Ravdin, Simon Read, Meredith M. Regan, J.F.R. Robertson, Emiel J. Rutgers, Suzy Scholl, Dennis J. Slamon, Lidija Sölkner, Joseph A. Sparano, Seth M. Steinberg, Rosemary Sutcliffe, Sandra M. Swain, Carolyn Taylor, Andrew Tutt, Pinuccia Valagussa, Cornelis J.�H. van de Velde, Jos A. van der Hage, Giuseppe Viale, Gϋnter von Minckwitz and 10 more - The Lancet Oncology 2017 cited by 1,133
- Anthracyclines: Molecular Advances and Pharmacologic Developments in Antitumor Activity and Cardiotoxicity
Authors: Giorgio Minotti, Pierantonio Menna, Emanuela Salvatorelli, Gaetano Cairo, Luca Gianni - Pharmacological Reviews 2004 cited by 3,728
- Four-year overall survival update from the phase III HIMALAYA study of tremelimumab plus durvalumab in unresectable hepatocellular carcinoma
Authors: B. Sangro, Stephen L. Chan, Robin Kate Kelley, George Lau, Masatoshi Kudo, Wattana Sukeepaisarnjaroen, M. Yarchoan, Enrico N. De Toni, J. Furuse, Yoon‐Koo Kang, Peter R. Galle, Lorenza Rimassa, Alexandra Heurgué, Vincent C. Tam, Tu Van Dao, S.C. Thungappa, В. В. Бредер, Y. Ostapenko, María Reig, M. Makowsky, Michael J. Paskow, Charu Gupta, John F. Kurland, Alejandra Negro, Ghassan K. Abou‐Alfa, Sérgio Santos de Azevêdo, Maria Ignez Braghiroli, Gustavo Girotto, Arinilda Campos Bragagnoli, Ricardo Branco, Adilson Faccio, Andrea Moretto, Nils Gunnar Skare, Jamille Dutra, Luciana Viola, Karina Vianna, Fernando Meton, Cláudia Vaz de Melo Sette, Amanda Faulhaber, Vincent C. Tam, Félix Couture, Jim Biagi, Hélène Castel, Karen Mulder, Yoo‐Joung Ko, Kevin Zbuk, Stephen Welch, Annie Beaudoin, Alexandra Heurgué, Éric Assenat, Isabelle Archambeaud, David Tougeron, Jean‐Marie Péron, Marine Gilabert, Jean–Pierre Bronowicki, Stéphane Cattan, Jean‐Frédéric Blanc, Mohamed Bouattour, Jean–Marc Phelip, Valérie Boige, Pierre Michel, Anne-Claire Frin, Enrico N. De Toni, Marie‐Luise Berres, Arndt Vogel, Thomas Berg, Thomas J. Ettrich, Dirk Waldschmidt, H. Wedemeyer, Marcus‐Alexander Wörns, Michael Bitzer, Karl-Heinz Weiss, George Lau, Stephen L. Chan, Thomas Yau, Y. Tai, Ann Shing Lee, Satheesh Chiradoni Thungappa, Lokesh K. N, Vikas Sureshchand Ostwal, Kattimani Kiran Ashok, Sushant Mittal, Hari Om Goyal, Sankar Srinivasan, Ghanashyam Biswas, Mallavarapu Mohan, Sewanti Limaye, Nirav Asarawala, Lorenza Rimassa, Alfredo Falcone, Luca Gianni, Antonio Gasbarrini, Bruno Daniele, Antonio Avallone, Giovanni Luca Frassineti, Fausto Roila, Masatoshi Kudo, Tomokazu Kawaoka, Manabu Morimoto, Yasuhiro Takikawa and 103 more - Annals of Oncology 2024 cited by 312
- Trastuzumab after Adjuvant Chemotherapy in HER2-Positive Breast Cancer
Authors: Martine Piccart, Marion Procter, Brian Leyland‐Jones, Aron Goldhirsch, Michael Untch, Ian Smith, Luca Gianni, José Baselga, Richard H. Bell, Christian Jackisch, David Cameron, Mitch Dowsett, Carlos H. Barrios, Günther Steger, Chiun‐Sheng Huang, Michael Andersson, Moshe Inbar, Mikhail Lichinitser, István Láng, Ulrike Nitz, Hiroji Iwata, Christoph Thomssen, Caroline Lohrisch, Thomas Suter, Josef Rüschoff, Tamás Sütö, Victoria Greatorex, Carol Ward, Carolyn Straehle, Eleanor McFadden, Mirko Dolci, Richard D. Gelber - New England Journal of Medicine 2005 cited by 5,098
- Pathologic complete response (pCR) to neoadjuvant treatment with or without atezolizumab in triple-negative, early high-risk and locally advanced breast cancer: NeoTRIP Michelangelo randomized study
Authors: Luca Gianni, Chiun‐Sheng Huang, Daniel Egle, Begoña Bermejo, C. Zamagni, Marc Thill, A. Antón, Stefania Zambelli, Giampaolo Bianchini, Salvatore Russo, Eva Ciruelos, Richard Greil, Semiglazov Vf, Marco Colleoni, Catherine M. Kelly, Gabriella Mariani, Lucia Del Mastro, I. Maffeis, Pinuccia Valagussa, Giuseppe Viale - Annals of Oncology 2022 cited by 386
- Trastuzumab emtansine versus capecitabine plus lapatinib in patients with previously treated HER2-positive advanced breast cancer (EMILIA): a descriptive analysis of final overall survival results from a randomised, open-label, phase 3 trial
Authors: Véronique Dièras, David Miles, Sunil Verma, Mark D. Pegram, Manfred Welslau, José Baselga, Ian E. Krop, Kim T. Blackwell, Silke Hoersch, Jin Xu, Marjorie Green, Luca Gianni - The Lancet Oncology 2017 cited by 656
- Durvalumab alone and durvalumab plus tremelimumab versus chemotherapy in previously untreated patients with unresectable, locally advanced or metastatic urothelial carcinoma (DANUBE): a randomised, open-label, multicentre, phase 3 trial
Authors: Thomas Powles, Michiel S. van der Heijden, Daniel Castellano, Matthew D. Galsky, Yohann Loriot, Daniel P. Petrylak, Osamu Ogawa, Se Hoon Park, Jae‐Lyun Lee, Ugo De Giorgi, Martin Bögemann, Aristotelis Bamias, Bernhard J. Eigl, Howard Gurney, Som D. Mukherjee, Yves Fradet, Iwona Skoneczna, Marinos Tsiatas, Andrey Novikov, Cristina Suárez, André P. Fay, Ignacio Durán, Andrea Necchi, Sophie Wildsmith, Philip He, Natasha Angra, Ashok Gupta, Wendy J. Levin, Joaquim Bellmunt, Se Hoon Park, Michiel S. van der Heijden, Andrea Necchi, Daniel Castellano, Aristotelis Bamias, Jae‐Lyun Lee, Ugo De Giorgi, Martin Bögemann, Bernhard J. Eigl, Marinos Tsiatas, Thomas Powles, Andrey Novikov, Iwona Skoneczna, Som D. Mukherjee, Cristina Suárez, Hans M. Westgeest, Yves Fradet, Aude Fléchon, Yen‐Chuan Ou, Inkeun Park, Vsevolod Matveev, Begoña Pérez‐Valderrama, Susanna Cheng, Stephen Jay Frank, Howard Gurney, Urbano Anido, Alketa Hamzaj, Margitta Retz, Srikala S. Sridhar, Giorgio V. Scagliotti, Jens Voortman, B. Yа. Alekseev, Anna Alyasova, B. K. Komyakov, Herlinde Dumez, Michel Pavic, Go Kimura, Atsushi Mizokami, Susanne Osanto, José Ángel Arranz, Djura Piersma, Sang Joon Shin, O. B. Karyakin, Ignacio Delgado, José Luis González, See‐Tong Pang, Anna Tran, Oleg Lipatov, Wen-Pin Su, Thomas W. Flaig, Ajjai Alva, Hwa Park Kyong, Evgeny Kopyltsov, Elena Almagro, M. Doménech, Yen‐Hwa Chang, Brieuc Sautois, Andre Ravaux, Gerasimos Aravantinos, V. Georgoulias, Sasja F. Mulder, Yu Jung Kim, Fabio Kater, Christine Chevreau, Scott T. Tagawa, Paweł Zalewski, Florence Joly, Yohann Loriot, Gencay Hatiboglu, Luca Gianni, Franco Morelli and 127 more - The Lancet Oncology 2020 cited by 498
- 11 years' follow-up of trastuzumab after adjuvant chemotherapy in HER2-positive early breast cancer: final analysis of the HERceptin Adjuvant (HERA) trial
Authors: David Cameron, Martine Piccart, Richard D. Gelber, Marion Procter, Aron Goldhirsch, Evandro de Azambuja, Gilberto de Castro, Michael Untch, Ian Smith, Luca Gianni, José Baselga, N. Al-Sakaff, Sabine Lauer, Eleanor McFadden, Brian Leyland‐Jones, Richard H. Bell, Mitch Dowsett, Christian Jackisch - The Lancet 2017 cited by 1,041
- 5-year analysis of neoadjuvant pertuzumab and trastuzumab in patients with locally advanced, inflammatory, or early-stage HER2-positive breast cancer (NeoSphere): a multicentre, open-label, phase 2 randomised trial
Authors: Luca Gianni, Tadeusz Pieńkowski, Young‐Hyuck Im, Ling‐Ming Tseng, Mei-Ching Liu, Aňa Lluch, Elżbieta Starosławska, Juan de la Haba-Rodríguez, Seock‐Ah Im, José Luiz Pedrini, Brigitte Poirier, Paolo Morandi, Semiglazov Vf, Vichien Srimuninnimit, Giulia Bianchi, Domenico Magazzù, Virginia McNally, Hannah Douthwaite, Graham Ross, Pinuccia Valagussa - The Lancet Oncology 2016 cited by 874
- Trastuzumab for early-stage, HER2-positive breast cancer: a meta-analysis of 13 864 women in seven randomised trials
Authors: Rosie Bradley, Jeremy Braybrooke, Richard J. Gray, Robert K. Hills, Zulian Liu, Richárd Pető, Lucy Davies, David Dodwell, Paul McGale, Hongchao Pan, Carolyn Taylor, Stewart Anderson, Richard D. Gelber, Luca Gianni, William Jacot, Heikki Joensuu, Alvaro Moreno‐Aspitia, Martine Piccart, Michael F. Press, Edward H. Romond, Dennis J. Slamon, Vera J. Suman, Richard Berry, Clare Boddington, Mike Clarke, Christina Davies, Frances Duane, Vaughan Evans, Jo Gay, Lucy Gettins, Jon Godwin, Sam James, Hui Liu, Elizabeth MacKinnon, Gurdeep Mannu, Theresa McHugh, Philip Morris, Simon Read, Ewan Straiton, Yaochen Wang, John Crown, Evandro de Azambuja, Suzette Delaloge, Helena Fung, Charles E. Geyer, M. Spielmann, Pinuccia Valagussa, Kathy S. Albain, Stewart Anderson, R. Arriagada, John Bartlett, Elizabeth Bergsten-Nordström, Judith M. Bliss, Étienne Brain, Lisa Carey, Robert E. Coleman, Jack Cuzick, Nancy E. Davidson, Lucia Del Mastro, Angelo Di Leo, James J. Dignam, Mitch Dowsett, Bent Ejlertsen, Prue Francis, Michael Gnant, Matthew Bidwell Goetz, Pam Goodwin, Pat Halpin-Murphy, Daniel Hayes, Catherine Hill, Reshma Jagsi, Wolfgang Janni, Sibylle Loibl, Eleftherios P. Mamounas, Miguel Martín, Hirofumi Mukai, Valentina Nekljudova, Larry Norton, Yasuo Ohashi, Lori J. Pierce, Philip Poortmans, Vinod Raina, Daniel Rea, Meredith M. Regan, J.F.R. Robertson, Emiel J. Rutgers, Tanja Španić, Joseph A. Sparano, Guenther G. Steger, Gong Tang, Masakazu Toi, Andrew Tutt, Giuseppe Viale, Xiang Wang, Timothy J. Whelan, Nicholas Wilcken, Norman Wolmark, David Cameron, Jonas Bergh, Kathleen I. Pritchard and 1 more - The Lancet Oncology 2021 cited by 348
- Final Results From the Randomized Phase III ASCENT Clinical Trial in Metastatic Triple-Negative Breast Cancer and Association of Outcomes by Human Epidermal Growth Factor Receptor 2 and Trophoblast Cell Surface Antigen 2 Expression
Authors: Aditya Bardia, Hope S. Rugo, Sara M. Tolaney, Delphine Loirat, Kevin Punie, Mafalda Oliveira, Adam Brufsky, Kevin Kalinsky, Javier Cortés, Joyce O' Shaughnessy, Véronique Dièras, Lisa A. Carey, Luca Gianni, Martine Piccart, Sibylle Loibl, Oh Kyu Yoon, Yang Pan, Scott Hofsess, See‐Chun Phan, Sara A. Hurvitz - Journal of Clinical Oncology 2024 cited by 153
- Neoadjuvant chemotherapy with trastuzumab followed by adjuvant trastuzumab versus neoadjuvant chemotherapy alone, in patients with HER2-positive locally advanced breast cancer (the NOAH trial): a randomised controlled superiority trial with a parallel HER2-negative cohort
Authors: Luca Gianni, W. Eiermann, Semiglazov Vf, Alexey Manikhas, Aňa Lluch, S. Tjulandin, Milvia Zambetti, Federico Vázquez, Mikhail Byakhow, Mikhail Lichinitser, Miguel Ángel Climent, Eva Ciruelos, B. Ojeda, Mauro Mansutti, А. А. Божок, Roberta Baronio, A. Feyereislova, Claire Barton, Pinuccia Valagussa, José Baselga - The Lancet 2010 cited by 1,268
- Treatment of HER2-positive breast cancer: current status and future perspectives
Authors: Carlos L. Arteaga, Mark X. Sliwkowski, C. Kent Osborne, Edith A. Perez, Fabio Puglisi, Luca Gianni - Nature Reviews Clinical Oncology 2011 cited by 871
- Adjuvant nab -Paclitaxel + Gemcitabine in Resected Pancreatic Ductal Adenocarcinoma: Results From a Randomized, Open-Label, Phase III Trial
Authors: Margaret A. Tempero, Uwe Pelzer, Eileen M. O’Reilly, Jordan M. Winter, Do‐Youn Oh, Chung‐Pin Li, Giampaolo Tortora, Heung-Moon Chang, Charles D. Lopez, Tanios Bekaii‐Saab, Andrew H. Ko, Armando Santoro, Joon Oh Park, Marcus Smith Noel, Giovanni Luca Frassineti, Yan‐Shen Shan, Andrew Dean, Hanno Riess, Eric Van Cutsem, Jordan Berlin, Philip Philip, Malcolm J. Moore, David Goldstein, Josep Tabernero, Mingyu Li, Stefano Ferrara, Yvan Le Bruchec, George Zhang, Brian Lu, Andrew V. Biankin, Michele Reni, Richard A. Epstein, Paul L. Vasey, Jeremy Shapiro, Matthew Burge, Yu Jo Chua, Marion Harris, Nick Pavlakis, Niall C. Tebbutt, Gerald W. Prager, Christian Dittrich, Friedrich Längle, Kathrin Philipp‐Abbrederis, Richard Greil, Herbert Stöger, Michael Girschikofsky, Thomas Kuehr, Jean–Luc Van Laethem, Stéphanie Laurent, Neesha C. Dhani, Yoo Joung Ko, Scot Dowden, Petr Kavan, Mustapha Édouard Tehfe, Eugen Kubala, Milan Kohoutek, Per Pfeiffer, Mette Yilmaz, Vibeke K. Parner, Tapio Salminen, Leena‐Maija Soveri, Eija Korkeila, Pia Österlund, Julien Taı̈eb, David Tougeron, Pascal Artru, François‐Xavier Caroli‐Bosc, Rosine Guimbaud, Antony Turpin, Thomas Walter, Jean‐Baptiste Bachet, Volker Kunzmann, Florian Kreth, Andreas De Block, Marino Venerito, Helmut Oettle, Meinolf Karthaus, Jörg Trojan, Gunnar Folprecht, Markus M. Lerch, Frank Kullmann, Marcel Reiser, Volker Heinemann, Marcus‐Alexander Wörns, H. Schulz, Benjamin Garlipp, Thomas Yau, Lam Stephen Chan, Balázs Juhász, László Landherr, Tamás Pintér, G. Bodoky, Zsuzsanna Kahán, Raymond McDermott, Derek G. Power, Luca Gianni, Salvatore Siena, Michèle Milella, Alfredo Falcone, Rossana Berardi and 87 more - Journal of Clinical Oncology 2022 cited by 132
- Safety analyses from the phase 3 ASCENT trial of sacituzumab govitecan in metastatic triple-negative breast cancer
Authors: Hope S. Rugo, Sara M. Tolaney, Delphine Loirat, Kevin Punie, Aditya Bardia, Sara A. Hurvitz, Joyce O’Shaughnessy, Javier Cortés, Véronique Dièras, Lisa A. Carey, Luca Gianni, Martine Piccart, Sibylle Loibl, David M. Goldenberg, Quan Hong, Martin Olivo, Loretta M. Itri, Kevin Kalinsky - npj Breast Cancer 2022 cited by 103
